Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNMD Mind Medicine (MindMed) Inc.

Market Closed 05-17 16:00:00 EDT

8.22

-0.43

-4.97%

盘后8.42

+0.20+2.43%

19:46 EDT

High8.78	Low8.22	Vol1.01M
Open8.67	D1 Closing8.65	Amplitude6.47%
Mkt Cap590.79M	Tradable Cap474.98M	Total Shares71.87M
T/O8.43M	T/O Rate1.74%	Tradable Shares57.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MNMD","market":"US","secType":"STK","nameCN":"Mind Medicine (MindMed) Inc.","latestPrice":8.22,"timestamp":1715976000000,"preClose":8.65,"halted":0,"volume":1006942,"hourTrading":{"tag":"盘后","latestPrice":8.4197,"preClose":8.22,"latestTime":"19:46 EDT","volume":20049,"amount":166213.9929,"timestamp":1715989612480},"delay":0,"floatShares":57783759,"shares":71872422,"eps":-3.017622,"marketStatus":"Market Closed","change":-0.43,"latestTime":"05-17 16:00:00 EDT","open":8.67,"high":8.78,"low":8.22,"amount":8428124.67884,"amplitude":0.06474,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.017622,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716192000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":8.65,"preHourTrading":{"tag":"盘前","latestPrice":8.7293,"preClose":8.65,"latestTime":"09:27 EDT","volume":4149,"amount":36151.651809,"timestamp":1715952445319},"postHourTrading":{"tag":"盘后","latestPrice":8.4197,"preClose":8.22,"latestTime":"19:46 EDT","volume":20049,"amount":166213.9929,"timestamp":1715989612480},"volumeRatio":0.908123},"requestUrl":"/m/hq/s/MNMD/wiki","defaultTab":"wiki","newsList":[{"id":"2434285920","title":"MindMed to Participate at May Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2434285920","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2434285920?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:01","pubTimestamp":1715284860,"startTime":"0","endTime":"0","summary":"NEW YORK, May 09, 2024----Mind Medicine  Inc.  , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:. Date and Time: Wednesday, May 15, 2024 at 11:00 am EDT. An audio webcast and replay of the fireside chat at the 2024 RBCCM Global Healthcare Conference will be accessible on MindMed’s Investor Relations website for up to 90 days following the event.MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zDRuMm2pNvaGPMhDtCCiWA--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0214e79fb62b9bd332b3dbf673d22a5d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zDRuMm2pNvaGPMhDtCCiWA--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0214e79fb62b9bd332b3dbf673d22a5d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-participate-may-investor-conferences-200100810.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434909486","title":"New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2434909486","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2434909486?lang=en_us&edition=fundamental","pubTime":"2024-05-09 20:00","pubTimestamp":1715256000,"startTime":"0","endTime":"0","summary":"Figure 1. Work Productivity: Absenteeism, presenteeism, overall work productivity loss and activity impairment: GAD by symptom severity vs. controls. Note: Groups that were statistically significant at p0.05, 2-tailed, compared with controls are marked with asterisks. Absenteeism, Presenteeism, and Overall work impairment were only applicable to those indicating they were currently working for pay. Absenteeism was not calculated for those who worked 0 hours and missed 0 hours in the last 7 days, and presenteeism was only asked among those who worked >0 hours in the last 7 days.  . Figure 2. Healthcare Resource Utilization: Number of HCP visits, ER visits, and hospitalizations within the past 6 months: undiagnosed GAD, no-GAD vs diagnosed GAD. Note: Groups that were statistically significant at p0.05, 2-tailed, compared with diagnosed GAD are marked with asterisks.  . \"These studies clearly demonstrate that the burden of GAD on the US healthcare system, employers, and people living with","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GAKgf3Oe0nNArH3gMWiF.A--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ee9f181709b110104940fc5f790e9e58","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GAKgf3Oe0nNArH3gMWiF.A--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ee9f181709b110104940fc5f790e9e58"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/studies-presented-international-society-health-120000158.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434060798","title":"Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2434060798","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2434060798?lang=en_us&edition=fundamental","pubTime":"2024-05-09 18:49","pubTimestamp":1715251740,"startTime":"0","endTime":"0","summary":"These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/05/biotech-breakthroughs-3-stocks-on-the-verge-of-revolutionizing-medicine/","is_publish_highlight":false,"gpt_icon":0},{"id":"2434702799","title":"MindMed Triumphs in Anxiety Treatment Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2434702799","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434702799?lang=en_us&edition=fundamental","pubTime":"2024-05-09 06:03","pubTimestamp":1715205800,"startTime":"0","endTime":"0","summary":"Mind Medicine Inc. (MNMD) has released an update. Mind Medicine Inc. has announced successful Phase 2b trial results for its anxiety treatment, MM1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mindmed-triumphs-in-anxiety-treatment-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mindmed-triumphs-in-anxiety-treatment-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434701902","title":"MindMed Files 8-K Report, Shares Trade on Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2434701902","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434701902?lang=en_us&edition=fundamental","pubTime":"2024-05-09 05:07","pubTimestamp":1715202447,"startTime":"0","endTime":"0","summary":"Mind Medicine Inc. (MNMD) has released an update. Mind Medicine (MindMed) Inc., a British Columbia-based company, has filed a current report on For...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mindmed-files-8-k-report-shares-trade-on-nasdaq?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mindmed-files-8-k-report-shares-trade-on-nasdaq?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434703314","title":"Mind Medicine Q1 2024 GAAP EPS $(1.14) Misses $(0.53) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434703314","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2434703314?lang=en_us&edition=fundamental","pubTime":"2024-05-09 04:03","pubTimestamp":1715198601,"startTime":"0","endTime":"0","summary":"Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(0.53) by 115.09 percent. This is a 75.38 percent decrease over losses of $(0.65) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38712087/mind-medicine-q1-2024-gaap-eps-1-14-misses-0-53-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2434260703","title":"Press Release: MindMed Reports First Quarter 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2434260703","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434260703?lang=en_us&edition=fundamental","pubTime":"2024-05-09 04:01","pubTimestamp":1715198460,"startTime":"0","endTime":"0","summary":"--Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder , demonstrating clinically and statistically significant activity through 12 weeks after treatment--. --The U.S. Food and Drug Administration  granted Breakthrough Therapy Designation to MM120 for the treatment of GAD in adults--. --Cash and cash equivalents of $252.3 million as of March 31, 2024--. --Company to host a conference call today at 4:30 p.m. EDT--. Mind Medicine  Inc. , , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.--  The Company completed an underwritten offering and concurrent private. placement for $175.0 million in gross proceeds before deducting. --  The Company voluntarily delisted its common shares from Cboe Canada.The Company's common shares continue to be listed and tradable on Nasdaq. --  In March ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432148272","title":"MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York","url":"https://stock-news.laohu8.com/highlight/detail?id=2432148272","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2432148272?lang=en_us&edition=fundamental","pubTime":"2024-05-04 20:00","pubTimestamp":1714824000,"startTime":"0","endTime":"0","summary":"-A single oral administration of MM120 100 g met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and a 48% clinical remission rate-. -MindMed also presents two new epidemiology studies quantifying the burden of GAD in the US-. -APA Annual Meeting, the largest psychiatric gathering in the world, is the first scientific presentation of MM120 Phase 2b data-. NEW YORK, May 04, 2024----Mind Medicine  Inc.  , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented data from MMED008, its Phase 2b study of MM120  in the treatment of GAD in adults. MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints. The study was presented at the APA Annual Meeting, the largest psychiatry-focused scientific meeting in th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/neXQtYH5pkdCrRWuqXaxug--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/478f7e39e06fb74e624a7e82ff529404","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/neXQtYH5pkdCrRWuqXaxug--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/478f7e39e06fb74e624a7e82ff529404"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-presents-phase-2b-study-120000301.html","is_publish_highlight":false,"gpt_icon":1},{"id":"2432676471","title":"Press Release: MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2432676471","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432676471?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:14","pubTimestamp":1714648440,"startTime":"0","endTime":"0","summary":"MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update. Mind Medicine  Inc.  , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the first quarter ended March 31, 2024.MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2431081171","title":"Psychedelic drug developers could benefit from NIH funding for chronic pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2431081171","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431081171?lang=en_us&edition=fundamental","pubTime":"2024-04-30 01:37","pubTimestamp":1714412227,"startTime":"0","endTime":"0","summary":"The National Institutes of Health recently announced it is offering $8.4M to support trials examining the efficacy and safety of psychedelic treatments for chronic pain. The notice, posted April 24, said that the research can include psilocybin , LSD, mescaline, and MDMA, also known as ecstasy.  \"A potential novel approach to treatment of chronic pain in adults involves psychedelic-assisted therapy ,\" the notice states. \"Evidence for the efficacy of PAT has been particularly notable in depression, anxiety , post-traumatic stress disorder , and substance use disorders, among other indications.\"  Marijuana Moment first reported the development on Monday. Several companies involved in developing psychedelic-based therapies could potentially benefit from the funding. These include Mind Medicine , Atai Life Sciences , Cybin , COMPASS Pathways , Lucy Scientific Discovery , 180 Life Sciences , Bright Binds Bioscience , and Seelos Theraspeutics .","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157676497/image_157676497.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157676497/image_157676497.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095746-psychedelic-drug-developers-could-benefit--nih-funding-chronic-pain","is_publish_highlight":false,"gpt_icon":0},{"id":"2430181223","title":"MindMed: Breakthrough Status From The FDA For LSD Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2430181223","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430181223?lang=en_us&edition=fundamental","pubTime":"2024-04-26 17:33","pubTimestamp":1714124023,"startTime":"0","endTime":"0","summary":"MindMed's LSD tartrate receives breakthrough therapy designation from the FDA for the treatment of generalized anxiety disorder.GAD affects a significant portion of the US population, with high costs ","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157611061/image_157611061.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157611061/image_157611061.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4686589-mindmed-breakthrough-status-from-the-fda-for-lsd","is_publish_highlight":false,"gpt_icon":0},{"id":"2430253467","title":"The Top 3 Small-Cap Stocks to Buy in April 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2430253467","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2430253467?lang=en_us&edition=fundamental","pubTime":"2024-04-26 03:00","pubTimestamp":1714071600,"startTime":"0","endTime":"0","summary":"These top small-cap stocks offer investors diversification across multiple segments but boast a strong standing on their own merits.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/04/the-top-3-small-cap-stocks-to-buy-in-april-2024/","is_publish_highlight":false,"gpt_icon":0},{"id":"2430409079","title":"MindMed to Present at Upcoming May Medical Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2430409079","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2430409079?lang=en_us&edition=fundamental","pubTime":"2024-04-25 19:00","pubTimestamp":1714042800,"startTime":"0","endTime":"0","summary":"NEW YORK, April 25, 2024----Mind Medicine  Inc. , , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder , as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:. American Psychiatric Association  2024 Congress, New York, NYTitle: Rapid and Durable Response to a Single Dose of MM120  in Generalized Anxiety Disorder: A Dose-Optimization StudyFormat: PosterPresenter: Dan Karlin, MDDate: Saturday, May 4, 2024. Title: Screening Adults in the US General Population to Detect Cases of Undiagnosed Generalized Anxiety DisorderFormat: PosterPresenter: Phong Duong, PharmDDate: Saturday, May 4, 2024. Certain statements in this news release related to the Company constitute \"forward-looking information\" within the meaning of applicable securities laws and","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/O74dO22ow3_3qUq0BEix_w--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/01847d73379adfa3faf512ce3e9854c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/O74dO22ow3_3qUq0BEix_w--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/01847d73379adfa3faf512ce3e9854c9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-present-upcoming-may-medical-110000793.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425994299","title":"MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2425994299","media":"Nasdaq","top":-1,"share":"https://ttm.financial/m/news/2425994299?lang=en_us&edition=fundamental","pubTime":"2024-04-08 20:32","pubTimestamp":1712579552,"startTime":"0","endTime":"0","summary":"MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMiU2h0dHBzOi8vd3d3Lm5hc2RhcS5jb20vYXJ0aWNsZXMvbWluZG1lZC1tbm1kLXN0b2NrLXJpc2VzLTE1NC1pbi0zLW1vbnRoczotaGVyZXMtd2h50gEA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMiU2h0dHBzOi8vd3d3Lm5hc2RhcS5jb20vYXJ0aWNsZXMvbWluZG1lZC1tbm1kLXN0b2NrLXJpc2VzLTE1NC1pbi0zLW1vbnRoczotaGVyZXMtd2h50gEA?oc=5","is_publish_highlight":false,"gpt_icon":0},{"id":"2425317186","title":"Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2425317186","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2425317186?lang=en_us&edition=fundamental","pubTime":"2024-04-05 00:43","pubTimestamp":1712249011,"startTime":"0","endTime":"0","summary":"I believe there is, because of the positive data reported for starters. Also, because the FDA granted MM-120 Breakthrough Therapy Designation [BTD], which means that MM-120 could ultimately be granted Priority Review by the FDA for submission. In addition, this biotech is not pinning its hopes on only this one clinical product. That's because it is also advancing another candidate, known as MM-402, which is an R-MDMA. In essence, an improved MDMA being explored in a phase 1 IIT UHB sponsored study for the treatment of patients with autism spectrum disorder [ASD]. Topline data from this early-stage study is expected in the 1st half of 2024. Lastly, there is another data readout to consider, which would be the use of LSD to treat patients with psychiatric disorders like major depressive disorder [MDD], cluster headaches and anxiety. MM-120 Achieves Necessary Outcome For Late-Stage Clinical Study Advancement As I noted above, Mind Medicine was able to report positive results from its phas","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1938555135/image_1938555135.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1938555135/image_1938555135.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4682186-mind-medicine-gad-program-success-continues-btd-positive-treatment-data","is_publish_highlight":false,"gpt_icon":0},{"id":"2424201841","title":"MindMed to Present at Upcoming April Medical Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2424201841","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2424201841?lang=en_us&edition=fundamental","pubTime":"2024-04-02 19:00","pubTimestamp":1712055600,"startTime":"0","endTime":"0","summary":"NEW YORK, April 02, 2024----Mind Medicine  Inc. , , , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:. European Psychiatric Association  2024 CongressTitle: Prevalence of Generalized Anxiety Disorder Among Five European Countries Before and During COVIDFormat: PosterPresenter: Phong Duong, PharmDDate and Time: Tuesday, April 9, 2024, at 9:30 AMLocation: Budapest, Hungary. Posters will be available on MindMed’s Company website following the conferences.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3oynAVIFPTubsP94GsbF1g--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/95f893ae1f6a6d89d48d4e3c2408cd92","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3oynAVIFPTubsP94GsbF1g--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/95f893ae1f6a6d89d48d4e3c2408cd92"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-present-upcoming-april-medical-110000027.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424701479","title":"Mind Medicine Inc. Statement Inaccessible","url":"https://stock-news.laohu8.com/highlight/detail?id=2424701479","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2424701479?lang=en_us&edition=fundamental","pubTime":"2024-04-02 07:37","pubTimestamp":1712014644,"startTime":"0","endTime":"0","summary":"Mind Medicine Inc. (MNMD) has released an update. Mind Medicine Inc. has released a new statement with significant updates that could interest inve...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mind-medicine-inc-statement-inaccessible?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mind-medicine-inc-statement-inaccessible?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2424379703","title":"BRIEF-Mindmed Announces Voluntary Delisting From Cboe Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2424379703","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2424379703?lang=en_us&edition=fundamental","pubTime":"2024-04-02 06:23","pubTimestamp":1712010216,"startTime":"0","endTime":"0","summary":"April 1  - Mind Medicine  Inc :   * MINDMED ANNOUNCES VOLUNTARY DELISTING FROM CBOE CANADA   * MIND MEDICINE  INC: ALL COMMON SHARES WILL REMAIN LISTED ON NASDAQ   * MIND MEDICINE  INC: ELECTED TO VOLUNTARILY DELIST ITS COMMON SHARES FROM CBOE CANADA, EFFECTIVE AT CLOSE OF MARKETS ON APRIL 10Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2424740557","title":"MindMed to voluntarily delist from CBOE Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2424740557","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424740557?lang=en_us&edition=fundamental","pubTime":"2024-04-02 05:10","pubTimestamp":1712005803,"startTime":"0","endTime":"0","summary":"Mind Medicine   has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed’s common shares will continue to be listed and tradable on The Nasdaq Global Select Market under the symbol “MNMD” and Canadian shareholders can continue to trade their shares on Nasdaq. The Company believes that the trading volume of its common shares on Cboe Canada no longer justifies the expense and administrative requirements associated with maintaining this dual listing. Source: Press Release    More on Mind Medicine  Mind Medicine  Inc.  Q4 2023 Earnings Call Transcript Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation Mind Medicine prices underwritten offering of shares and concurrent private placement","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4086032-mindmed-to-voluntarily-delist-from-cboe-canada","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mindmed.co","stockEarnings":[{"period":"1week","weight":-0.1123},{"period":"1month","weight":-0.1375},{"period":"3month","weight":0.6707},{"period":"6month","weight":2.1737},{"period":"1year","weight":1.6095},{"period":"ytd","weight":1.2459}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.138746},{"month":2,"riseRate":1,"avgChangeRate":0.220255},{"month":3,"riseRate":0.333333,"avgChangeRate":0.135594},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.020489},{"month":5,"riseRate":0.25,"avgChangeRate":-0.052353},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.089764},{"month":7,"riseRate":0.666667,"avgChangeRate":0.117736},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.029688},{"month":9,"riseRate":0,"avgChangeRate":-0.380307},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.087807},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.018305},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.110398}],"exchange":"NASDAQ","name":"Mind Medicine (MindMed) Inc.","nameEN":"Mind Medicine (MindMed) Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mind Medicine (MindMed) Inc.,MNMD,Mind Medicine (MindMed) Inc.股票,Mind Medicine (MindMed) Inc.股票老虎,Mind Medicine (MindMed) Inc.股票老虎国际,Mind Medicine (MindMed) Inc.行情,Mind Medicine (MindMed) Inc.股票行情,Mind Medicine (MindMed) Inc.股价,Mind Medicine (MindMed) Inc.股市,Mind Medicine (MindMed) Inc.股票价格,Mind Medicine (MindMed) Inc.股票交易,Mind Medicine (MindMed) Inc.股票购买,Mind Medicine (MindMed) Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction